ECSP21082527A - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Info

Publication number
ECSP21082527A
ECSP21082527A ECSENADI202182527A ECDI202182527A ECSP21082527A EC SP21082527 A ECSP21082527 A EC SP21082527A EC SENADI202182527 A ECSENADI202182527 A EC SENADI202182527A EC DI202182527 A ECDI202182527 A EC DI202182527A EC SP21082527 A ECSP21082527 A EC SP21082527A
Authority
EC
Ecuador
Prior art keywords
eye diseases
sema3a
antibodies
treat eye
sema3a antibodies
Prior art date
Application number
ECSENADI202182527A
Other languages
English (en)
Inventor
Kristin Bovat
Juergen Prestle
Nina Zippel
Sanjaya Singh
Rajkumar Ganesan
Leo Thomas
Dongmei Liu
Sathyadevi Venkataramani
Rachel Barrett
Fei Han
Helen Wu
Priyanka Gupta
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP21082527A publication Critical patent/ECSP21082527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre semaforina 3A (Sema3A). Más específicamente, se divulgan anticuerpos anti-Sema3A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
ECSENADI202182527A 2019-05-09 2021-11-18 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares ECSP21082527A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09

Publications (1)

Publication Number Publication Date
ECSP21082527A true ECSP21082527A (es) 2021-12-30

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202182527A ECSP21082527A (es) 2019-05-09 2021-11-18 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Country Status (27)

Country Link
US (3) US11267880B2 (es)
EP (1) EP3966239A1 (es)
JP (2) JP7314310B2 (es)
KR (1) KR20220007128A (es)
CN (1) CN113795509A (es)
AR (1) AR122266A1 (es)
AU (1) AU2020267874A1 (es)
BR (1) BR112021019854A2 (es)
CA (1) CA3137377A1 (es)
CL (1) CL2021002795A1 (es)
CO (1) CO2021014768A2 (es)
CR (1) CR20210559A (es)
DO (1) DOP2021000226A (es)
EA (1) EA202193038A1 (es)
EC (1) ECSP21082527A (es)
IL (1) IL287758A (es)
JO (1) JOP20210300A1 (es)
MA (1) MA55872A (es)
MX (1) MX2021013671A (es)
MY (1) MY206253A (es)
PE (1) PE20220287A1 (es)
PH (1) PH12021552776A1 (es)
SA (1) SA521430793B1 (es)
SG (1) SG11202110842QA (es)
TW (1) TWI836069B (es)
UA (1) UA129953C2 (es)
WO (1) WO2020225400A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY206253A (en) * 2019-05-09 2024-12-05 Boehringer Ingelheim Int Anti-sema3a antibodies and their uses for treating eye or ocular diseases
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
US12384843B2 (en) 2021-03-30 2025-08-12 Bayer Aktiengesellschaft Anti-semaphorin 3A antibodies
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP2497498A4 (en) * 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
WO2013005603A1 (ja) 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
US9879075B2 (en) 2013-02-06 2018-01-30 Yokohama City University and Chiome Bioscience Inc. Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
US9822367B2 (en) * 2013-02-21 2017-11-21 Rsem, Limited Partnership Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
PL3189074T3 (pl) * 2014-09-05 2021-08-02 Rsem, Limited Partnership Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AU2016346595B2 (en) 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
MY206253A (en) * 2019-05-09 2024-12-05 Boehringer Ingelheim Int Anti-sema3a antibodies and their uses for treating eye or ocular diseases

Also Published As

Publication number Publication date
US20200385446A1 (en) 2020-12-10
EA202193038A1 (ru) 2022-03-30
CN113795509A (zh) 2021-12-14
JP2022531698A (ja) 2022-07-08
WO2020225400A1 (en) 2020-11-12
AR122266A1 (es) 2022-08-31
JOP20210300A1 (ar) 2023-01-30
AU2020267874A1 (en) 2021-10-28
JP7638332B2 (ja) 2025-03-03
JP7314310B2 (ja) 2023-07-25
JP2023130473A (ja) 2023-09-20
PH12021552776A1 (en) 2022-09-19
CO2021014768A2 (es) 2021-11-19
CA3137377A1 (en) 2020-11-12
DOP2021000226A (es) 2021-12-15
MX2021013671A (es) 2021-12-10
CL2021002795A1 (es) 2022-08-05
TWI836069B (zh) 2024-03-21
US20240336674A1 (en) 2024-10-10
KR20220007128A (ko) 2022-01-18
MY206253A (en) 2024-12-05
NZ780763A (en) 2025-09-26
US20220144929A1 (en) 2022-05-12
US11267880B2 (en) 2022-03-08
IL287758A (en) 2022-01-01
SA521430793B1 (ar) 2024-03-28
SG11202110842QA (en) 2021-10-28
TW202108621A (zh) 2021-03-01
PE20220287A1 (es) 2022-02-25
EP3966239A1 (en) 2022-03-16
UA129953C2 (uk) 2025-09-24
MA55872A (fr) 2022-03-16
CR20210559A (es) 2021-12-23
BR112021019854A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
ECSP21082527A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
MX2021015501A (es) Anticuerpos y metodos de uso.
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
MX2021013004A (es) Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos.
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
CL2023000955A1 (es) Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombótica de la retina
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.